01 - 03 MARCH, 2024
BALI NUSA DUA CONVENTION CENTER, BALI, INDONESIA

CONFERENCE BOOKLET

01 MARCH, 2024
SURGICAL WORKSHOP
BEST OF SAN ANTONIO BREAST CANCER
ONCOLOGY NURSING SESSION
HANDS ON IMAGING WORKSHOP

IN COLLABORATION WITH

ORGANIZED BY
apbcs.org
REACHING NEW HEIGHTS IN BREAST CANCER CARE
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>CONTENT</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>WELCOME NOTE FROM ORGANIZING COMMITTEE</td>
<td>04</td>
</tr>
<tr>
<td>APBCS 2024 SCIENTIFIC COMMITTEE</td>
<td>05</td>
</tr>
<tr>
<td>SURGICAL WORKSHOP FACULTY</td>
<td>06</td>
</tr>
<tr>
<td>HANDS-ON IMAGING WORKSHOP FACULTY</td>
<td>07</td>
</tr>
<tr>
<td>ONCOLOGY NURSING SESSION FACULTY</td>
<td>07</td>
</tr>
<tr>
<td>BEST OF SABCS FACULTY</td>
<td>08</td>
</tr>
<tr>
<td>APBCS 2024 FACULTY</td>
<td>09</td>
</tr>
<tr>
<td>PROGRAM AT GLANCE</td>
<td>14</td>
</tr>
<tr>
<td>DAY 1: PRE-CONFERENCE WORKSHOP</td>
<td>15</td>
</tr>
<tr>
<td>• SURGICAL WORKSHOP PROGRAM</td>
<td>16</td>
</tr>
<tr>
<td>• HANDS-ON IMAGING WORKSHOP PROGRAM</td>
<td>17</td>
</tr>
<tr>
<td>• ONCOLOGY NURSING SESSION PROGRAM</td>
<td>18</td>
</tr>
<tr>
<td>• BEST OF SABCS PROGRAM</td>
<td>19</td>
</tr>
<tr>
<td>DAY 2 - SCIENTIFIC PROGRAM</td>
<td>21</td>
</tr>
<tr>
<td>DAY 3 - SCIENTIFIC PROGRAM</td>
<td>24</td>
</tr>
<tr>
<td>OUR INDUSTRY PARTNERS</td>
<td>27</td>
</tr>
<tr>
<td>OUR SUPPORTERS</td>
<td>28</td>
</tr>
</tbody>
</table>
Esteemed Colleagues and Friends,

Warm greetings,

Asia Pacific Breast Cancer Summit (APBCS) over the years has evolved into a premiere platform in the field of breast cancer management in the Asia-Pac region for over 12 years. Our scientific and organizing committee are relentlessly working towards bringing the best global, regional, and local experts and research to enhance the patient care, aligning to its theme, “Reaching New Heights in Breast Cancer Care.”

The impact of APBCS has been resounding in various APAC region, and Indonesia marks the next chapter in the journey for its 12th edition in 2024. The scientific and organizing committee of APBCS 2024 edition would like to extend a warm welcome to each one of you from 1st – 3rd March, 2024 at Nusa Dua Convention Centre in Bali, Indonesia. APBCS 2024 edition will feature stellar key opinion leaders from across the globe to share insights in the realm of Breast Cancer. Over 3 days, the agenda will include Surgical Oncology Session, Oncology Nursing Session, Imaging Session, Best of SABCS review, and in-depth discussions on advanced findings, recent developments, molecular tumor board, challenging cases within APBCS.

APBCS 2024 promises to be a gathering of minds dedicated to pushing the boundaries of knowledge in the field of Breast Cancer.

We cordially invite you to join us in Bali, Indonesia, for an invaluable opportunity to learn, network, and collaborate with esteemed colleagues and peers.

Best regards,

APBCS 2024 Committee
Dr. Rebecca Dent | Dr. Shaheena Dawood | Dr. Lee Soo Chin
SURGICAL WORKSHOP FACULTY

BENITA TAN
SINGAPORE

FARIDA BRIANI
INDONESIA

GEOK HOON LIM
SINGAPORE

JULIE LIANA
SINGAPORE

LESTER LEONG
SINGAPORE

LIM SUE ZANN
SINGAPORE

MOK CHI WEI
SINGAPORE

OEY CHUNG LIE
SINGAPORE

PETER DUBSKY
SWITZERLAND

SEE MEE HOONG
MALAYSIA

VERONIQUE TAN
SINGAPORE
HANDS-ON IMAGING WORKSHOP

ARIS ROSATI
INDONESIA

KARDINAH
INDONESIA

TEO SZE YIUN
SINGAPORE

ONCOLOGY NURSING SESSION FACULTY

ADELE WOON
SINGAPORE

BARKAH ISNAINI
INDONESIA

CAHYO WIBISONO
INDONESIA

ELEN NOVILIA
INDONESIA

JENNIFER LEWELLYN
USA

KRISTIN MARIE FERGUSON
USA

NURDIANA ISMANGIL
INDONESIA
BEST OF SABCS FACULTY

FAYE LIM
SINGAPORE

HOPE RUGO
USA

JAVIER CORTES
SPAIN

LEE SOO CHIN
SINGAPORE

PETER DUBSKY
SWITZERLAND

TIRA TAN
SINGAPORE
ALBAN DIEN  
INDONESIA  

ANDHIKA RANCHMAN  
INDONESIA  

AVA KWONG  
HONG KONG  

AZRIF MOHAMMAD  
MALAYSIA  

CHAO NI  
CHINA  

BENITA TAN  
SINGAPORE  

CHENG HAR YIP  
MALAYSIA  

COSPHIADI IRAWAN  
INDONESIA  

DAKSA GANAPATI  
INDONESIA  

DENNY HANDOYO  
INDONESIA  

DIANI KARTINI  
INDONESIA  

DJUMHANA ATMAKUSUMA  
INDONESIA
APBCS 2024 FACULTY

KARMEN WONG
SINGAPORE

KILEY LOH
SINGAPORE

HANDOKO
INDONESIA

LALIT KUMAR RADHA KRISHNA
SINGAPORE

LEE SOO CHIN
SINGAPORE

MABEL WONG
SINGAPORE

TIARA BUNGA MAYANG PERMATA
INDONESIA

NADIA AYU MULANSARI
INDONESIA

NI G.A. ARINI JUNITA PUTRI KARDINAL
INDONESIA

NIRMALA BHOO PATHY
MALAYSIA

PETER DUBSKY
SWITZERLAND

PHILIP POORTSMAN
BELGIUM
APBCS 2024 FACULTY

PORNSIRA HONGSAKUL  
THAILAND

RADEN YOHANA  
INDONESIA

RALPH GIRSON GUNARSA  
INDONESIA

RINI ANDARINI  
INDONESIA

ROGER DANIEL VAUGHAN  
SINGAPORE

RONALD HUKOM  
INDONESIA

SAMUEL J. HARYONO  
INDONESIA

SAMUEL OW  
SINGAPORE

SAWITRI DARMIATI  
INDONESIA

SHAHEENAH DAWOOD  
UAE

SHYAM SHRIVASTAVA  
INDIA

SOEHARTATI GONDHOWIARDJO  
INDONESIA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 – 08:25</td>
<td>Welcome Remarks</td>
</tr>
</tbody>
</table>
| 08:25 – 08:45| Breast Ultrasound and US guided percutaneous biopsy techniques – what every breast surgeon should know  
  **Lester Leong, Singapore** |
| 08:45 – 09:00| From bedside to OT – how the breast US is now an essential tool for the Breast Surgical Oncologist  
  **Mok Chi Wei, Singapore** |
| 09:00 – 09:15| Breast Conserving Surgery vs Mastectomy – The Final Decision  
  **See Mee Hoong, Malaysia** |
| 09:15 – 09:30| BCS in Asia – Challenges & advances to date  
  **Farida Briani, Indonesia** |
| 09:30 – 10:00| Coffee Break                                                           |
| 10:00 – 11:00| **Satellite Symposium by MSD**  
  Elevating Patient Outcomes at Early-Stage TNBC: Immunotherapy and Surgical Practice?  
  **Chair: Farida Briani, Indonesia**  
  **Speaker: Benita Tan, Singapore** |
| 11:00 – 12:00| Hands-on Workshop  
  • Use of US machine -tips and tricks / US features of malignancy  
  • US guided FNA  
  • US guided trucut  
  • US guided VAB  
  • US guided clip placement |
| Table Instructors: **Lester Leong, Singapore | See Mee Hoong, Malaysia  
  Mok Chi Wei, Singapore | Benita Tan, Singapore  
  Lim Sue Zann, Singapore | Julie Liana, Singapore  
  Oey Chung Lie, Singapore | Peter Dubsky, Switzerland |
| 12:00         | Closing Remarks & Lunch Break                                           |
13:50 - 14:00 Welcome Remarks
14:00 – 14:20 Explore the benefits of using 3D Automated Breast US in multidisciplinary approach
Teo Sze Yiun, Singapore
14:20 – 14:50 Contrast-Enhanced Mammography: Applications in Clinical Practice
Teo Sze Yiun, Singapore
14:50 – 15:20 The Superiority of MRI in Detecting Breast Cancer
Ari Rosati, Indonesia
15:20 – 15:30 Q&A – Lead by Dr. Kardinah
15:30 – 15:50 Coffee Break
15:50 – 16:20 Marching Forward and Reinforcing Breast Ultrasound Early Detection in Indonesia
Kardinah, Indonesia
16:20 - 16:30 AI Ultrasound fun quiz – GE Healthcare
16:30 - 17:30 GE Healthcare Breast Care Product Showcase Tour
17:30 Closing Remarks
08:30 Welcome Remarks

08:30 - 09:15 Antineoplastic Medication Overview
Overview of classes of each type of systemic treatment (chemotherapy, hormonal agents, targeted therapies and immunotherapy)
Jennifer Lewellyn, USA

09:15 - 09:35 Breakout Session
Small group discussions with group leader asking questions
Facilitators: Jennifer Lewellyn, USA | Kristin Marie Ferguson, USA
Adele Woon, Singapore | Barkah Isnaini, Indonesia
Cahyo Wibisono, Indonesia | Elen Novilia, Indonesia
Nurdiana Ismangil, Indonesia

09:35 - 10:05 Side Effect Management
Overview of general chemotherapy – induced side effects: Evidence-based assessment tools, prevention and management of common toxicities (Fatigue, myelosuppression, nausea and vomiting)
Kristin Marie Ferguson, USA

10:05 - 10:30 Breakout Session
Small group discussions with group leader asking questions
Facilitators: Jennifer Lewellyn, USA | Kristin Marie Ferguson, USA
Adele Woon, Singapore | Barkah Isnaini, Indonesia
Cahyo Wibisono, Indonesia | Elen Novilia, Indonesia
Nurdiana Ismangil, Indonesia

10:30 - 11:00 Coffee Break

11:00 - 11:45 Process of Drug Administration & Safe Handling of Hazardous Drugs
Steps in the administration process, safety checks, preparation, and administration considerations. Includes dose calculations during verification; Exposure risks, related adverse health effects, types of exposure, types of controls for exposure, drug administration best practices, handling body fluids and waste, managing spills and exposures
Jennifer Lewellyn, USA

11:45 - 12:05 Breakout Session
Small group discussions with group leader asking questions
Facilitators: Jennifer Lewellyn, USA | Kristin Marie Ferguson, USA
Adele Woon, Singapore | Barkah Isnaini, Indonesia
Cahyo Wibisono, Indonesia | Elen Novilia, Indonesia
Nurdiana Ismangil, Indonesia

12:05 - 13:00 Breast Cancer
Incidence, risk factors, physiology, presentation, staging and treatment overview
Kristin Marie Ferguson, USA

13:00 Closing Remarks
01 March, 2024 (Friday) 14:00 – 16:40 Hrs Bali, Indonesia Time SINGARAJA 1

14:00 – 14:30 Screening and Surgical Oncology
Speaker: Peter Dubsky, Switzerland

- GS03-02: Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
- GS02-02: Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
- GS02-06: Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection - first results from the international randomized SENOMAC trial
- GS02-04: Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival

14:30 – 15:00 Radiation Oncology
Speaker: Faye Lim, Singapore

- GS02-07: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
- GS02-08: Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favourable Stage I breast cancer
- GS03-01: Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112

15:00 – 15:30 Early-Stage Hormone Receptor Positive Breast Cancer
Speaker: Javier Cortes, Spain

- GS1-01: Biomarker results in high-risk estrogen receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer following neoadjuvant chemotherapy + nivolumab: an exploratory analysis of CheckMate7FL
- GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2- breast cancer: KEYNOTE-756
- GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial
- GS03-06: Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
15:30 - 16:00 | Early stage Triple Negative Breast Cancer/HER2 positive Breast Cancer/Survivorship
Speaker: **Tira Tan, Singapore**
- **GS01-03**: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
- **GS03-12**: Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis
- **GS02-11**: Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
- **GS02-13**: Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study

16:00 - 16:20 | Advanced Triple Negative and HER2 positive negative Breast Cancer
Speaker: **Hope Rugo, USA**
- **GS01-05**: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
- **GS01-10**: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer

16:20 - 16:40 | Advanced ER Positive HER2 Negative Breast Cancer
Speaker: **Lee Soo Chln, Singapore**
- **GS02-01**: Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01
- **GS05-13**: Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis
- **GS01-12**: MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer
DAY 2

APBCS SCIENTIFIC PROGRAM

📅 02 MARCH, 2024

🕒 08:00 - 16:45
HRS BALI TIME
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td>Welcome Coffee</td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>Satellite Symposium by AstraZeneca</td>
</tr>
<tr>
<td></td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Nadia Ayu Mulansari, Indonesia</td>
</tr>
<tr>
<td></td>
<td><strong>Exploring Advanced Paths: Strategic Approach in Managing HER2-Positive Breast Cancer</strong></td>
</tr>
<tr>
<td></td>
<td>- Overview of current HER2-positive treatment landscape globally and within the Asia region</td>
</tr>
<tr>
<td></td>
<td>- Provide context of the unmet need surrounding therapeutic options for HER2- Positive and Her- 2 Low treatment</td>
</tr>
<tr>
<td></td>
<td>- Real-world insights and experiences in T-Dxd adverse event management</td>
</tr>
<tr>
<td></td>
<td>- Strategic Approach in Managing Brain Metastases in HER2- Positive Breast Cancer Patients</td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Shaheenah Dawood, UAE</td>
</tr>
<tr>
<td></td>
<td><strong>Panel Discussion, Summary and Closing</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Nadia Ayu Mulansari, Indonesia</td>
</tr>
<tr>
<td></td>
<td><strong>Panel:</strong> Shaheenah Dawood, UAE</td>
</tr>
</tbody>
</table>

**Session 1: The Evolving Landscape of HER 2 Positive Disease**

**Chairperson:** Lee Soo Chin, Singapore | Ikhwan Rinaldi, Indonesia

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30-09:50</td>
<td>Does One Size Fit all for Neoadjuvant/Adjuvant Therapy in HER2+ Breast Cancer? Javier Cortes, Spain</td>
</tr>
<tr>
<td>09:50 - 10:05</td>
<td>Optimal Sequencing of Therapy in Metastatic HER2 + MBC in South East Asia Lee Soo Chin, Singapore</td>
</tr>
<tr>
<td>10:05-10:45</td>
<td>Tumor Board 1: Challenging Cases in HER2 Positive Disease (i.e. Changing Receptor Status from Preop to Residual Disease, Brain Mets etc.)</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator</strong> Samuel Ow, Singapore</td>
</tr>
<tr>
<td></td>
<td><strong>Panel:</strong> Javier Cortes, Spain</td>
</tr>
<tr>
<td></td>
<td>**Nadia Ayu Mulansari, Indonesia</td>
</tr>
<tr>
<td>10:45 – 11:00</td>
<td>Coffee Break and Poster Viewing</td>
</tr>
<tr>
<td>11:00 – 12:00</td>
<td>Satellite Symposium by MSD</td>
</tr>
<tr>
<td></td>
<td>Advancing Breast Cancer Care: Immunotherapy in early TNBC treatment</td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Nadia Ayu Mulansari, Indonesia</td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Hope Rugo, USA</td>
</tr>
</tbody>
</table>
Session 2: Challenging Questions in Triple Negative Breast Cancer
Chairperson: Sung Bae Kim, South Korea | Sonar Soni Panigoro, Indonesia

12:00 - 12:15  Standards of Care in Early TNBC  
Jeffry Beta Tenggara, Indonesia

12:15 - 12:30  Anything New to Offer Patients with Metastatic TNBC?  
Tira Tan, Singapore

12:30 - 12:45  Unique Issues in TNBC  
Andhika Rahman, Indonesia

12:45 - 13:30  Tumor Board 2: Challenging Cases in TNBC  
Moderator: Shaheenah Dawood, UAE | Ralph Girson Gunarsa, Indonesia  
Panel: Peter Dubsky, Switzerland | Hope Rugo, USA  
Benita Tan, Singapore | Wong Nan Soon, Singapore  
Raden Yohana, Indonesia | Jeffry Beta Tenggara, Indonesia  
Alban Dien, Indonesia | Carmen Wong, Singapore  
Ni G.A. Arini Junita Putri Kardinal, Indonesia

13:30 - 14:30  Lunch Break

Session 3: Hormone Receptor Positive Breast Cancer: Escalating and De-escalating Therapy
Chairperson: Yap Yoon Sim, Singapore | Irianiwati Widodo, Indonesia | Ronald Hukom, Indonesia

14:30 - 14:45  Do we need or not need adjuvant chemotherapy in hormonal receptor positive-HER2 negative EBC?  
Cosphiadi Irawan, Indonesia

14:45 - 15:00  Optimizing local therapy in ER+ early breast cancer  
Peter Dubsky, Switzerland

15:00 - 15:30  Satellite Symposium by Pfizer  
Navigating Through CDK4/6 Inhibitors Clinical Trial and Real World-Based Evidence  
Hope Rugo, USA

15:30 - 15:45  Q &A

15:45 - 16:45  Tumor Board 3: Challenging Issues in HR+ve Breast Cancer  
Moderator: Kiley Loh, Malaysia | Peter Dubsky, Switzerland  
Panel: Djamuna Atmakusuma, Indonesia | Yap Yoon Sim, Singapore  
Hope Rugo, USA | Janice Tsang, Hong Kong | Jack Chan, Singapore  
Ava Kwong, Hong Kong | Azrif Mohammad, Malaysia | Cheng Har Yip, Malaysia  
Diani Kartini, Indonesia | Denny Handoyo, Indonesia  
I Wayan Losen Adnyana | Chao Ni, China

16:45  Day 1 Closing Remarks and Poster Viewing
DAY 3

APBCS SCIENTIFIC PROGRAM

03 MARCH, 2024

09:00 – 15:40
HRS BALI TIME
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Welcome Coffee</td>
</tr>
<tr>
<td>09:30</td>
<td><strong>Session 4: Genomics for Breast Cancer</strong></td>
</tr>
<tr>
<td>09:30</td>
<td>How and Why Would I Order a Genetic Test? BRCA Testing Made Easy</td>
</tr>
<tr>
<td>09:55</td>
<td>Are you interpreting the genetic test result correctly?</td>
</tr>
<tr>
<td>10:10</td>
<td>HR positive HER2 negative and Bone Metastasis: Genomic Point of View</td>
</tr>
<tr>
<td>10:25</td>
<td>Germline focused Molecular Tumor Board</td>
</tr>
<tr>
<td>11:05</td>
<td>Satellite Symposium by Roche</td>
</tr>
<tr>
<td>11:35</td>
<td>Coffee Break and Poster Viewing</td>
</tr>
<tr>
<td>11:50</td>
<td><strong>Session 5: The People's Choice Selection for Advanced Stage Breast Cancer</strong></td>
</tr>
<tr>
<td>11:50</td>
<td>Challenging Cases in Advanced Breast Cancer Radiotherapy</td>
</tr>
<tr>
<td>12:05</td>
<td>Collaborative Advancement in Radiation Oncology for Breast Cancer Control</td>
</tr>
<tr>
<td>12:20</td>
<td>How to deliver bad news?</td>
</tr>
<tr>
<td>12:35</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>12:45</td>
<td>Lunch Break</td>
</tr>
</tbody>
</table>

**Moderator**: Samuel Ow, Singapore | Zhang Zewen, Singapore

**Panel**: Lee Soo Chin, Singapore | Ava Kwong, Hong Kong
Faye Lim, Singapore | Soo Teo Hwang, Malaysia
Endang Nuryadi, Indonesia | Ikhwan Rinaldi, Indonesia

**Topic**: Rewriting the patient experience with subcutaneous formulation of HER2-targeted antibodies

Benefits and practicality of applying subcutaneous HER2 targeted antibodies in breast cancer treatment
- Brief overview of PH FDC SC
- Addressing potential concerns on fixed dose SC injections for patients with lower body weight

**Speaker**: Lee Soo Chin, Singapore

**Facilitator**: Lee Soo Chin, Singapore

**Panel**: Nadia Ayu Mulansari, Indonesia | Iris Wong, Hong Kong
Pornsira Hongsakul, Thailand
### Session 6: Hot topics in Breast Cancer
Chairperson: Mabel Wong, Singapore | Soehartati Gondhowiardjo, Indonesia

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45 - 14:05</td>
<td>Women, Power and Cancer: A Lancet Commission</td>
<td><strong>Nirmala Bhoo Pathy, Malaysia</strong></td>
</tr>
<tr>
<td>14:05 - 14:15</td>
<td>A New Ally in Cancer Care: The Role of Coaching from a Survivor's Perspective</td>
<td><strong>Isabel Galiano, Singapore</strong></td>
</tr>
<tr>
<td>14:15 - 14:35</td>
<td>Statistics made easy for understanding oncology trials</td>
<td><strong>Roger Vaughan, Singapore</strong></td>
</tr>
<tr>
<td>14:35 - 14:45</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>14:45 - 15:35</td>
<td>Case Discussion: Brain mets</td>
<td>**Moderator: Daksa Ganapati, Indonesia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>**Panel: Nadia Ayu Mulansari, Indonesia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>**Sawitri Darmiati, Indonesia</td>
</tr>
<tr>
<td>15:35 - 15:40</td>
<td>Closing Remarks</td>
<td></td>
</tr>
</tbody>
</table>
OUR INDUSTRY PARTNERS

OFFICIAL HEALTHCARE PARTNER

MRCCC Siloam Hospitals

MAIN SPONSOR

MSD

PLATINUM SPONSOR

AstraZeneca

GOLD SPONSORS

Roche Pfizer

SILVER SPONSOR

GE Healthcare
LOCAL SUPPORTERS

REGIONAL SUPPORTERS

PUBLISHING PARTNER

INTERNATIONAL AFFILIATION
SAVE THE DATE

JOURNEY CONTINUES

SEE YOU NEXT YEAR IN SINGAPORE!